Hormone assays are essential tests for the diagnosis, treatment, and prevention of certain chronic diseases such as diabetes and osteoporosis. According to the Partnership for the Accurate Testing of Hormones (PATH),
when two laboratories use different tests to measure a hormone level, they may get different results for the same patient even though they use the same sample. These inaccurate test results can lead to a misdiagnosis and/or
a delayed or incorrect treatment.
Contact Laura DeStigter to learn more about NACDD’s work on laboratory standardization and biomarkers.
NACDD Action on Biomarkers
NACDD collaborates with CDC, the Endocrine Society, and PATH in a partnership to improve
the quality of laboratory measurements for chronic disease biomarkers. The strategic plan advocates for the universal adoption of accuracy-based testing in medical practice and research to advance the development of standardized
chronic disease biomarker tests. As a result, NACDD has created a detailed brochure explaining how clinical standardization can improve the diagnosis, detection, and treatment of chronic diseases.